Clinical value of protein expression of kallikrein-related peptidase 7 (KLK7) in ovarian cancer

Biological Chemistry

Volumn 395, Issue 1, 2014, Pages 95-107

  Dorn, Julia ^a   Gkazepis, Apostolos ^a   Kotzsch, Matthias ^b   Kremer, Marcus ^a   Propping, Corinna ^a   Mayer, Katharina ^a   Mengele, Karin ^a   Diamandis, Eleftherios P ^c   Kiechle, Marion ^a   Magdolen, Viktor ^a   Schmitt, Manfred ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

ELISA; immunohistochemistry; kallikrein related peptidases; prognosis; tumor tissue

Indexed keywords

STRATUM CORNEUM CHYMOTRYPTIC ENZYME;

ADULT; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER TISSUE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN CONTENT; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TISSUE LEVEL; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KALLIKREINS; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84890406716     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/hsz-2013-0172     Document Type: Article

References (47)

1. Avgeris, M., Mavridis, K., and Scorilas, A. (2010). Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies. Biol. Chem. 391, 505-511.
2. Bast, R.C., Badgwell, D., Lu, Z., Marquez, R., Rosen, D., Liu, J., Baggerly, K.A., Atkinson, E.N., Skates, S., Zhang, Z., et al. (2005). New tumour markers: CA125 and beyond. Int. J. Gynecol. Cancer 15, 274-281.
3. Bignotti, E., Tassi, R.A., Calza, S., Ravaggi, A., Romani, C., Rossi, E., Falchetti, M., Odicino, F.E., Pecorelli, S., and Santin, A.D. (2006). Differential gene expression profiles between tumour biopsies and short-term primary cultures of ovarian serous carcinomas: Identification of novel molecular biomarkers for early diagnosis and therapy. Gynecol. Oncol. 103, 405-416.
4. Borgono, C.A. and Diamandis, E.P. (2004). The emerging roles of human tissue kallikreins in cancer. Nat. Rev. Cancer 4, 876-890.
5. Cannistra, S.A. (2004). Cancer of the ovary. N. Engl. J. Med. 24, 2519-2529.
6. Caubet, C., Jonca, N., Brattsand, M., Guerrin, M., Bernard, D., Schmidt, R., Egelrud, T., Simon, M., and Serre, G. (2004). Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7. J. Invest. Dermatol. 122, 1235-1244.
7. Clarke, C.H., Yip, C., Badgwell, D., Fung, E.T., Coombes, K.R., Zhang, Z., Lu, K.H., and Bast, R.C., Jr. (2011). Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. Gynecol. Oncol. 122, 548-553.
8. Conway, C., Dobson, L., O'Grady, A., Kay, E., Costello, S., and O'Shea, D. (2008). Virtual microscopy as an enabler of automated/quantitative assessment of protein expression in TMAs. Histochem. Cell Biol. 130, 447-463.
9. Dong, Y., Kaushal, A., Brattsand, M., Nicklin, J., and Clements, J.A. (2003). Differential splicing of KLK5 and KLK7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers. Clin. Cancer Res. 9, 1710-1720.
10. Dong, Y., Tan, O.L., Loessner, D., Stephens, C., Walpole, C., Boyle, G.M., Parsons, P.G., and Clements, J.A. (2010). Kallikreinrelated peptidase 7 promotes multicellular aggregation via the 51 integrin pathway and paclitaxel chemoresistance in serous epithelial ovarian carcinoma. Cancer Res. 70, 2624-2633.
11. Dorn, J., Harbeck, N., Kates, R., Magdolen, V., Grass, L., Soosaipillai, A., Schmalfeldt, B., Diamandis, E.P., and Schmitt, M. (2006). Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma. Biol. Chem. 8, 1121-1128.
12. Dorn, J., Schmitt, M., Kates, R., Schmalfeldt, B., Kiechle, M., Scorilas, A., Diamandis, E.P., and Harbeck, N. (2007). Primary tumour levels of human tissue kallikreins impact surgical success and survival in ovarian cancer patients. Clin. Cancer Res. 13, 1742-1748.
13. Dorn, J., Magdolen, V., Gkazepis, A., Gerte, T., Harlozinska, A., Sedlaczek, P., Diamandis, E.P., Schuster, T., Harbeck, N., Kiechle, M., et al. (2011a). Circulating biomarker tissue kallikrein-related peptidase KLK5 impacts ovarian cancer patients' survival. Ann. Oncol. 22, 1783-1790.
14. Dorn, J., Harbeck, N., Kates, R., Gkazepis, A., Scorilas, A., Soosaipillai, A., Diamandis, E., Kiechle, M., Schmalfeldt, B., and Schmitt, M. (2011b). Impact of expression differences of KLK and of uPA and PAI-1 between primary tumour and omentum metastasis in advanced ovarian cancer. Ann. Oncol. 22, 877-883.
15. Gabril, M., White, N.M., Moussa, M., Chow, T.F., Metias, S.M., Fatoohi, E., and Yousef, G.M. (2010). Immunohistochemical analysis of kallikrein-related peptidases in the normal kidney and renal tumours: Potential clinical implications. Biol. Chem. 391, 403-409.
16. Girgis, A.H., Bui, A., White, N.M., and Yousef, G.M. (2012). Integrated genomic characterization of the kallikrein gene locus in cancer. Anticancer Res. 32, 957-963.
17. Hansson, L., Strömqvist, M., Bäckman, A., Wallbrandt, P., Carlstein, A., and Egelrud, T. (1994). Cloning, expression, and characterization of stratum corneum chymotryptic enzyme. A skin-specific human serine proteinase. J. Biol. Chem. 269, 19420-19426.
18. Hibbs, K., Skubitz, K.M., Pambuccian, S.E., Casey, R.C., Burleson, K.M., Oegema, T.R., Jr., Thiele, J.J., Grindle, S.M., Bliss, R.L., and Skubitz, A.P. (2004). Differential gene expression in ovarian carcinoma: Identification of potential biomarkers. Am. J. Pathol. 165, 397-414.
19. Høgdall, E., Fung, E.T., Christensen, I.J., Yip, C., Nedergaard, L., Engelholm, S.A., Risum, S., Petri, A.L., Lundvall, L., Lomas, L., et al. (2010). Proteomic biomarkers for overall and progressionfree survival in ovarian cancer patients. Proteomics Clin. Appl. 4, 940-952.
20. Holzscheiter, L., Biermann, J.C., Kotzsch, M., Prezas, P., Farthmann, J., Baretton, G., Luther, T., Tjan-Heijnen, V.C., Talieri, M., Schmitt, M., et al. (2006). Quantitative reverse transcription-PCR assay for detection of mRNA encoding full-length human tissue kallikrein 7: Prognostic relevance of KLK7 mRNA expression in breast cancer. Clin. Chem. 52, 1070-1079.
21. Kim, Y.W., Bae, S.M., Lim, H., Kim, Y.J., and Ahn, W.S. (2012). Development of multiplexed bead-based immunoassays for the detection of early stage ovarian cancer using a combination of serum biomarkers. PLoS One 7, e44960.
22. Kishi, T., Grass, L., Soosaipillai, A., Scorilas, A., Harbeck, N., Schmalfeldt, B., Dorn, J., Mysliwiec, M., Schmitt, M., and Diamandis, E.P. (2003). Human kallikrein 8, a novel biomarker for ovarian carcinoma. Cancer Res. 63, 2771-2774.
23. Kotzsch, M., Bernt, K., Friedrich, K., Luther, E., Albrecht, S., Gatzweiler, A., Magdolen, V., Baretton, G., Zietz, C., and Luther T. (2010). Prognostic relevance of tumour cell-associated uPAR expression in invasive ductal breast carcinoma. Histopathology 57, 461-471.
24. Kyriakopoulou, L.G., Yousef, G.M., Scorilas, A., Katsaros, D., Massobrio, M., Fracchioli, S., and Diamandis, E.P. (2003). Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer. Clin. Biochem. 36, 135-143.
25. Lang, D.S., Heilenkötter, U., Schumm, W., Behrens, O., Simon, R., Vollmer, E., and Goldmann, T. (2013). Optimized immunohistochemistry in combination with image analysis: A reliable alternative to quantitative ELISA determination of uPA and PAI-1 for routine risk group discrimination in breast cancer. Breast, Jan 15. DOI:pii: S0960-9776(12)00255-X. 10.1016/j. breast.2012.12.011.
26. Macuks, R., Baidekalna, I., and Donina, S. (2012). An ovarian cancer malignancy risk index composed of HE4, CA125, ultrasonographic score, and menopausal status: Use in differentiation of ovarian cancers and benign lesions. Tumour Biol. 33, 1811-1817.
27. Mangé, A., Desmetz, C., Berthes, M.L., Maudelonde, T., and Solassol, J. (2008). Specific increase of human kallikrein 4 mRNA and protein levels in breast cancer stromal cells. Biochem. Biophys. Res. Commun. 375, 107-112.
28. Oikonomopoulou, K., Li, L., Zheng, Y., Simon, I., Wolfert, R.L., Valik, D., Nekulova, M., Simickova, M., Frgala, T., and Diamandis, E.P. (2008). Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel. Br. J. Cancer 99, 1103-1113.
29. Paliouras, M. and Diamandis, E.P. (2006). The kallikrein world: An update on the human tissue kallikreins. Biol. Chem. 387, 643-652.
30. Petraki, C.D., Papanastasiou, P.A., Karavana, V.N., and Diamandis, E.P. (2006). Cellular distribution of human tissue kallikreins: Immunohistochemical localization. Biol. Chem. 387, 653-663.
31. Psyrri, A., Kountourakis, P., Scorilas, A., Markakis, S., Camp, R., Kowalski, D., Diamandis, E.P., and Dimopoulos, M.A. (2008). Human tissue kallikrein 7, a novel biomarker for advanced ovarian carcinoma using a novel in situ quantitative method of protein expression. Ann. Oncol. 19, 1271-1277.
32. Rosen, D.G., Wang, L., Atkinson, J.N., Yu, Y., Lu, K.H., Diamandis, E.P., Hellstrom, I., Mok, S.C., Liu, J., and Bast, R.C. (2005). Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol. Oncol. 99, 267-277.
33. Schmitt, M., Mengele, K., Gkazepis, A., Napieralski, R., Magdolen, V., Reuning, U., and Harbeck, N. (2008). Assessment of urokinase-type plasminogen activator and its inhibitor PAI-1 in breast cancer tissue: Historical aspects and future prospects. Breast Care 3, 3-10.
34. Seiz, L., Dorn, J., Kotzsch, M., Walch, A., Grebenchtchikov, N.I., Gkazepis, A., Schmalfeldt, B., Kiechle, M., Bayani, M., Diamandis, E.P., et al. (2012). Stromal cell-associated expression of kallikrein-related peptidase 6 (KLK6) indicates poor prognosis of ovarian cancer patients. Biol. Chem. 393, 391-401.
35. Shan, S.J., Scorilas, A., Katsaros, D., Rigault, de la Longrais, I., Massobrio, M., and Diamandis, E.P. (2006). Unfavorable prognostic value of human kallikrein 7 quantified by ELISA in ovarian cancer cytosols. Clin. Chem. 52, 1879-1886.
36. Shaw, J. and Diamandis, E.P. (2007). Distribution of 15 human kallikreins in tissues and biological fluids. Clin. Chem. 53, 1423-1432.
37. Swisher, E.M., Taniguchi, T., and Karlan, B.Y. (2012). Molecular scores to predict ovarian cancer outcomes: A worthy goal, but not ready for prime time. J. Natl. Cancer Inst. 104, 642-645.
38. Talieri, M., Diamandis, E.P., Gourgiotis, D., Mathioudaki, K., and Scorilas, A. (2004). Expression analysis of the human kallikrein 7 (KLK7) in breast tumours: A new potential biomarker for prognosis of breast carcinoma. Thromb. Haemost. 91, 180-186.
39. Talieri, M., Mathioudaki, K., Prezas, P., Alexopoulou, D.K., Diamandis, E.P., Xynopoulos, D., Ardavanis, A., Arnogiannaki, N., and Scorilas, A. (2009). Clinical significance of kallikrein-related peptidase 7 (KLK7) in colorectal cancer. Thromb. Haemost. 101, 741-747.
40. Termini, L., Maciag, P.C., Soares, F.A., Nonogaki, S., Pereira, S.M., Alves, V.A., Longatto-Filho, A., and Villa, L.L. (2010). Analysis of human kallikrein 7 expression as a potential biomarker in cervical neoplasia. Int. J. Cancer 127, 485-490.
41. Uzunoglu, S., Aybatl, A., Kaplan, P.B., Cicin, I., Sut, N., Sayn, C., and Varol, F. (2013). Assessment of CA-125 area under the curve as a prognostic factor in patients with ovarian cancer. Med. Oncol. 30, 447.
42. Whitehouse, C. and Solomon, E. (2003). Current status of the molecular characterization of the ovarian cancer antigen CA125 and implications for its use in clinical screening. Gynecol. Oncol. 88, 152-157.
43. Xuan, Q., Yang, X., Mo, L., Huang, F., Pang, Y., Qin, M., Chen, Z., He, M., Wang, Q., and Mo, Z.N. (2008). Expression of the serine protease kallikrein 7 and its inhibitor antileukoprotease is decreased in prostate cancer. Arch Pathol. Lab. Med. 132, 1796-1801.
44. Yip, P., Chen, T.H., Seshaiah, P., Stephen, L.L., Michael-Ballard, K.L., Mapes, J.P., Mansfield, B.C., and Bertenshaw, G.P. (2011). Comprehensive serum profiling for the discovery of epithelial ovarian cancer biomarkers. PLoS One 6, e29533.
45. Yoshida, S., Furukawa, N., Haruta, S., Tanase, Y., Kanayama, S., Noguchi, T., Sakata, M., Yamada, Y., Oi, H., and Kobayashi, H. (2009). Expression profiles of genes involved in poor prognosis of epithelial ovarian carcinoma: A review. Int. J. Gynecol. Cancer 19, 992-997.
46. Yousef, G.M. and Diamandis, E.P. (2009). The human kallikrein gene family: New biomarkers for ovarian cancer. Cancer Treat. Res. 149, 165-187.
47. Zheng, Y., Katsaros, D., Shan, S.J., de la Longrais, I.R., Porpiglia, M., Scorilas, A., Kim, N.W., Wolfert, R.L., Simon, I., Li, L., et al. (2007). A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy. Clin. Cancer Res. 13, 6984-6992.